Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCI-779 in Soft Tissue Sarcoma
NCT00087074Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2004
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in soft tissue sarcoma (STS) and gastrointestinal stromal tumor (GIST), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 6 months. Started Jun 2004; status: completed.
02
Drugs
temsirolimus
03
Conditions
soft tissue sarcoma (STS)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00087074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087074.